To impact the established market, the platform would need to find a more tolerogenic sweet spot, as well as offer major efficacy advantages.Īnd yet, it’s no sure thing that mRNA will prove capable of effectively delivering haemagglutinin glycoproteins, the main antigen found in flu vaccines.
MRNA “is a tool that does offer some upside potential,” says Gary Nabel, former CSO of Sanofi, the founding director of the NIH’s Vaccine Research Center (VRC), and CEO of the stealth-stage immunotherapeutics company ModeX Therapeutics.
These same symptoms can occur with approved flu shots, but typically are much milder in degree. Moderna and Pfizer/BioNTech’s authorized mRNA jabs for COVID-19 often cause sore arms, headaches, low-grade fevers and fatigue. All of these features could translate into greater immune protection.īut mRNA, at least when formulated in lipid nanoparticles (LNPs), is prone to tolerability issues. In theory, mRNA might make for a better product: elicited immune responses may be broader, expressed proteins should have better sequence fidelity, strain selection may be more accurate and the technology makes it easy to incorporate large numbers of antigens. Existing flu shots, whether built around inactivated viruses or recombinant proteins, typically offer only 40–60% protection from infection. Those vaccines are safe, but their efficacy leaves room for improvement. That’s because unlike with SARS-CoV-2 - for which there were no established medical interventions - nine flu jabs from four different vaccine manufacturers are already available in the United States alone. NIAID, National Institute of Allergy and Infectious Diseases saRNA, self-amplifying RNA.īut flu shots could also prove a more challenging test for mRNA than did COVID-19.
AMRT-5400 and MRT-5401 rely on non-modified RNA.
0 kommentar(er)
